Toll Free: 1-888-928-9744

Congestive Heart Failure (Heart Failure) - Pipeline Review, H2 2017

Published: Aug 8, 2017 | Pages: 396 | Publisher: Global Markets Direct | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Congestive Heart Failure (Heart Failure) - Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Congestive Heart Failure (Heart Failure) - Pipeline Review, H2 2017, provides an overview of the Congestive Heart Failure (Heart Failure) (Cardiovascular) pipeline landscape.

Heart failure is also known as congestive heart failure (CHF). CHF is a condition in which the heart is no longer able to pump out enough oxygen-rich blood. Symptoms include cough, fatigue, weakness, faintness, loss of appetite, swollen (enlarged) liver or abdomen, swollen feet and ankles and weight gain. The predisposing factors include high blood pressure, diabetes, sleep apnea, alcohol use and irregular heartbeats. Treatment includes surgery, vasodilator, beta blockers and diuretics. 

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Congestive Heart Failure (Heart Failure) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Congestive Heart Failure (Heart Failure) (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Congestive Heart Failure (Heart Failure) (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Congestive Heart Failure (Heart Failure) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 19, 27, 17, 2, 43, 11 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 19 and 8 molecules, respectively.

Congestive Heart Failure (Heart Failure) (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Congestive Heart Failure (Heart Failure) (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Congestive Heart Failure (Heart Failure) (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Congestive Heart Failure (Heart Failure) (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Congestive Heart Failure (Heart Failure) (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
- The pipeline guide reviews latest news related to pipeline therapeutics for Congestive Heart Failure (Heart Failure) (Cardiovascular)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Congestive Heart Failure (Heart Failure) (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Congestive Heart Failure (Heart Failure) (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
 Table of Contents
Table of Contents 2 Introduction 5 Congestive Heart Failure (Heart Failure) - Overview 6 Congestive Heart Failure (Heart Failure) - Therapeutics Development 7 Congestive Heart Failure (Heart Failure) - Therapeutics Assessment 26 Congestive Heart Failure (Heart Failure) - Companies Involved in Therapeutics Development 40 Congestive Heart Failure (Heart Failure) - Drug Profiles 75 Congestive Heart Failure (Heart Failure) - Dormant Projects 360 Congestive Heart Failure (Heart Failure) - Discontinued Products 366 Congestive Heart Failure (Heart Failure) - Product Development Milestones 368 Appendix 380
List of Tables
Number of Products under Development for Congestive Heart Failure (Heart Failure), H2 2017 Number of Products under Development by Companies, H2 2017 Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017 Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017 Number of Products under Development by Companies, H2 2017 (Contd..4), H2 2017 Number of Products under Development by Universities/Institutes, H2 2017 Number of Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017 Products under Development by Companies, H2 2017 Products under Development by Companies, H2 2017 (Contd..1), H2 2017 Products under Development by Companies, H2 2017 (Contd..2), H2 2017 Products under Development by Companies, H2 2017 (Contd..3), H2 2017 Products under Development by Companies, H2 2017 (Contd..4), H2 2017 Products under Development by Companies, H2 2017 (Contd..5), H2 2017 Products under Development by Companies, H2 2017 (Contd..6), H2 2017 Products under Development by Universities/Institutes, H2 2017 Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017 Number of Products by Stage and Target, H2 2017 Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017 Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017 Number of Products by Stage and Target, H2 2017 (Contd..3), H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..3), H2 2017 Number of Products by Stage and Route of Administration, H2 2017 Number of Products by Stage and Molecule Type, H2 2017 Congestive Heart Failure (Heart Failure) - Pipeline by Acorda Therapeutics Inc, H2 2017 Congestive Heart Failure (Heart Failure) - Pipeline by Amgen Inc, H2 2017 Congestive Heart Failure (Heart Failure) - Pipeline by AnGes MG Inc, H2 2017 Congestive Heart Failure (Heart Failure) - Pipeline by Araim Pharmaceuticals Inc, H2 2017 Congestive Heart Failure (Heart Failure) - Pipeline by Arbor Pharmaceuticals LLC, H2 2017 Congestive Heart Failure (Heart Failure) - Pipeline by Ascendia Pharmaceuticals LLC, H2 2017 Congestive Heart Failure (Heart Failure) - Pipeline by AstraZeneca Plc, H2 2017 Congestive Heart Failure (Heart Failure) - Pipeline by Athersys Inc, H2 2017 Congestive Heart Failure (Heart Failure) - Pipeline by Bayer AG, H2 2017 Congestive Heart Failure (Heart Failure) - Pipeline by BEAT BioTherapeutics Corp, H2 2017 Congestive Heart Failure (Heart Failure) - Pipeline by BioCardia Inc, H2 2017 Congestive Heart Failure (Heart Failure) - Pipeline by BlueRock Therapeutics, H2 2017 Congestive Heart Failure (Heart Failure) - Pipeline by Boehringer Ingelheim GmbH, H2 2017 Congestive Heart Failure (Heart Failure) - Pipeline by Bristol-Myers Squibb Company, H2 2017 Congestive Heart Failure (Heart Failure) - Pipeline by C&C BioPharma LLC, H2 2017 Congestive Heart Failure (Heart Failure) - Pipeline by Capricor Therapeutics Inc, H2 2017 Congestive Heart Failure (Heart Failure) - Pipeline by Celixir Ltd, H2 2017 Congestive Heart Failure (Heart Failure) - Pipeline by Celyad SA, H2 2017 Congestive Heart Failure (Heart Failure) - Pipeline by Egalet Corp, H2 2017 Congestive Heart Failure (Heart Failure) - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017 Congestive Heart Failure (Heart Failure) - Pipeline by FibroGen Inc, H2 2017 Congestive Heart Failure (Heart Failure) - Pipeline by Galenica Ltd, H2 2017 Congestive Heart Failure (Heart Failure) - Pipeline by GlaxoSmithKline Plc, H2 2017 Congestive Heart Failure (Heart Failure) - Pipeline by Heart Metabolics Ltd, H2 2017 Congestive Heart Failure (Heart Failure) - Pipeline by Hemostemix Ltd, H2 2017 Congestive Heart Failure (Heart Failure) - Pipeline by Immunwork Inc, H2 2017 Congestive Heart Failure (Heart Failure) - Pipeline by Innopharmax Inc, H2 2017 Congestive Heart Failure (Heart Failure) - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2017 Congestive Heart Failure (Heart Failure) - Pipeline by Johnson & Johnson, H2 2017 Congestive Heart Failure (Heart Failure) - Pipeline by Juventas Therapeutics Inc, H2 2017 Congestive Heart Failure (Heart Failure) - Pipeline by La Jolla Pharmaceutical Company, H2 2017 Congestive Heart Failure (Heart Failure) - Pipeline by Lead Discovery Center GmbH, H2 2017 Congestive Heart Failure (Heart Failure) - Pipeline by Lee's Pharmaceutical Holdings Ltd, H2 2017 Congestive Heart Failure (Heart Failure) - Pipeline by Les Laboratoires Servier SAS, H2 2017 Congestive Heart Failure (Heart Failure) - Pipeline by Lonestar Heart Inc, H2 2017 Congestive Heart Failure (Heart Failure) - Pipeline by Madeleine Pharmaceuticals Inc, H2 2017 Congestive Heart Failure (Heart Failure) - Pipeline by Merck & Co Inc, H2 2017 Congestive Heart Failure (Heart Failure) - Pipeline by Mesoblast Ltd, H2 2017 Congestive Heart Failure (Heart Failure) - Pipeline by MorphoSys AG, H2 2017 Congestive Heart Failure (Heart Failure) - Pipeline by N-Gene Research Laboratories Inc, H2 2017 Congestive Heart Failure (Heart Failure) - Pipeline by NanoCor Therapeutics Inc, H2 2017 Congestive Heart Failure (Heart Failure) - Pipeline by Neurocrine Biosciences Inc, H2 2017 Congestive Heart Failure (Heart Failure) - Pipeline by Novartis AG, H2 2017 Congestive Heart Failure (Heart Failure) - Pipeline by Nuo Therapeutics Inc, H2 2017 Congestive Heart Failure (Heart Failure) - Pipeline by Orion Oyj, H2 2017 Congestive Heart Failure (Heart Failure) - Pipeline by Palatin Technologies Inc, H2 2017 Congestive Heart Failure (Heart Failure) - Pipeline by Paradigm Biopharmaceuticals Ltd, H2 2017 Congestive Heart Failure (Heart Failure) - Pipeline by PharmaIN Corp, H2 2017 Congestive Heart Failure (Heart Failure) - Pipeline by PhaseBio Pharmaceuticals Inc, H2 2017 Congestive Heart Failure (Heart Failure) - Pipeline by Quantum Genomics SA, H2 2017 Congestive Heart Failure (Heart Failure) - Pipeline by Recardio GmbH, H2 2017 Congestive Heart Failure (Heart Failure) - Pipeline by Renova Therapeutics Inc, H2 2017 Congestive Heart Failure (Heart Failure) - Pipeline by Sarfez Pharmaceuticals Inc, H2 2017 Congestive Heart Failure (Heart Failure) - Pipeline by Savara Inc, H2 2017 Congestive Heart Failure (Heart Failure) - Pipeline by scPharmaceuticals Inc, H2 2017 Congestive Heart Failure (Heart Failure) - Pipeline by Stealth BioTherapeutics Inc, H2 2017 Congestive Heart Failure (Heart Failure) - Pipeline by Stemedica Cell Technologies Inc, H2 2017 Congestive Heart Failure (Heart Failure) - Pipeline by Takeda Pharmaceutical Company Ltd, H2 2017 Congestive Heart Failure (Heart Failure) - Pipeline by Theravance Biopharma Inc, H2 2017 Congestive Heart Failure (Heart Failure) - Pipeline by TiGenix NV, H2 2017 Congestive Heart Failure (Heart Failure) - Pipeline by Torrent Pharmaceuticals Ltd, H2 2017 Congestive Heart Failure (Heart Failure) - Pipeline by Trevena Inc, H2 2017 Congestive Heart Failure (Heart Failure) - Pipeline by U.S. Stem Cell Inc, H2 2017 Congestive Heart Failure (Heart Failure) - Pipeline by Vicore Pharma AB, H2 2017 Congestive Heart Failure (Heart Failure) - Pipeline by XyloCor Therapeutics Inc, H2 2017 Congestive Heart Failure (Heart Failure) - Pipeline by Zensun (Shanghai) Sci & Tech Co Ltd, H2 2017 Congestive Heart Failure (Heart Failure) - Dormant Projects, H2 2017 Congestive Heart Failure (Heart Failure) - Dormant Projects, H2 2017 (Contd..1), H2 2017 Congestive Heart Failure (Heart Failure) - Dormant Projects, H2 2017 (Contd..2), H2 2017 Congestive Heart Failure (Heart Failure) - Dormant Projects, H2 2017 (Contd..3), H2 2017 Congestive Heart Failure (Heart Failure) - Dormant Projects, H2 2017 (Contd..4), H2 2017 Congestive Heart Failure (Heart Failure) - Dormant Projects, H2 2017 (Contd..5), H2 2017 Congestive Heart Failure (Heart Failure) - Discontinued Products, H2 2017 Congestive Heart Failure (Heart Failure) - Discontinued Products, H2 2017 (Contd..1), H2 2017


List of Figures
Number of Products under Development for Congestive Heart Failure (Heart Failure), H2 2017 Number of Products under Development by Companies, H2 2017 Number of Products under Development by Universities/Institutes, H2 2017 Number of Products by Top 10 Targets, H2 2017 Number of Products by Stage and Top 10 Targets, H2 2017 Number of Products by Top 10 Mechanism of Actions, H2 2017 Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017 Number of Products by Routes of Administration, H2 2017 Number of Products by Stage and Routes of Administration, H2 2017 Number of Products by Top 10 Molecule Types, H2 2017 Number of Products by Stage and Top 10 Molecule Types, H2 2017

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

U.S hairbrush market is estimated to exceed USD 1.2 billion by 2022, as per a new research report by Radiant Insights, Inc. Rising population along with ascending disposable income is expected to drive industry demand. Significant rise in disposable

Read More...

Global engineering service outsourcing market size is likely to be valued at USD 415.7 billion by 2020, as per a new research report by Radiant Insights, Inc. Rapid alignment of OEMs accompanied by increasing focus on efficient performance and reliab

Read More...

Global coated fabrics market size forecast is estimated at USD 22.57 billion by 2020; as per a new research report by Radiant Insights, Inc. Increasing production of seat covers & airbags for automobile applications is likely to favor market growth.

Read More...

Global sorbitol market size is anticipated to be reach USD 3.99 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing consumer perception towards product benefits derived from natural ingredients is expected to drive the dem

Read More...

Global non destructive testing equipment market is anticipated to reach USD 5.76 billion by 2022, as per a new research report by Radiant Insights, Inc. Stringent government safety initiatives for inspection and quality control across numerous indust

Read More...
Choose License Type
Single User - US $2000
Multi User - US $4000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify